Scientists have detected altered glycometabolic control, insulin resistance and an abnormal cytokine profile in COVID-19 patients and glycaemic abnormalities can be detected for at least 2 months in patients who recovered from COVID-19 (Montefusco et al., 2021).Recent studies have shown that GP73 is a gluconeogenic hormone that contributes to SARS-CoV-2-induced hyperglycaemia by promoting hepatic gluconeogenesis. This evidence concerns the gene INS and Hyperglycemia.